The value and limitations of contrast-enhanced ultrasound in detection of prostate cancer

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1421-1426

  Strazdiņa, Arta ^a   Krumiņa, Gaida ^a   Sperga, Maris ^b  

^a RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^b State Agency Infectology Center of Latvia   (Latvia)

Author keywords

Contrast enhanced ultrasonography; Prostate cancer; Transrectal ultrasonography

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; SULFUR HEXAFLUORIDE;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER SIZE; CLINICAL ARTICLE; CONTRAST ENHANCED ULTRASONOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECHOGRAPHY; HUMAN; INTERMETHOD COMPARISON; MALE; MORPHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY ANALYSIS; TRANSRECTAL ULTRASONOGRAPHY; VISIBILITY;

ADENOCARCINOMA; CONTRAST MEDIA; HUMANS; LIMIT OF DETECTION; MALE; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 79956127762     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP and Zattoni F: EAU guidelines on prostate cancer. Eur Urol 53: 68-80, 2008. (Pubitemid 350166735)
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Gerald L and Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324(17): 1156-1161, 1991.
3. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL and Lange PH: Screening for prostatic carcinoma with prostate-specific antigen: J Urol 147: 841-845, 1992.
4. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ and Coltman CA Jr: Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng per milliliter. N Engl J Med 350: 2239-2246, 2004.
5. Murthy GD, Byron DP and Pasquale D: Underutilization of digital rectal examination when screening prostate cancer. Arch Intern Med 164: 313-316, 2004. (Pubitemid 38176471)
6. Lee F Jr, Bronson JP, Lee F, Torp-Pedersen ST, Siders DB, Thornbury JR and McHugh TA: Nonpalpable cancers of prostate: assesment with transrectal US. Radiology 178: 197-199, 1991.
7. De la Rosette JM and Aarnik RG: New developments in ultrasonography for detection of prostate cancer. J Endourol 15(1): 93-104, 2001.
8. Rifkin MD, Dahnert W and Kurtz AB: State of art: endorectal sonography of the prostate gland. Am J Roentgenol 154: 691-700, 1990.
9. Oyen R, Van Popel H, Van de Voorde W, Knapen P, Ameye F, Baert AL and Baert LV: The significance of focal hypoechoic lesions in the peripheral zone of the prostate. J Belge Radiol 78: 356-358, 1995. (Pubitemid 26048938)
10. Sibley RI and Sibley AF: Correlation of digital rectal examination, prostatic specific antigen and transrectal ultrasound in prostate carcinoma in African-Americans. J Natl Med Assoc 89: 318-323, 1997. (Pubitemid 127459613)
11. Norberg M, Egevad L, Holmberg P, Sparen P, Norlen BJ and Busch C: The sextant protocol for ultrasound-guided core biopsies of prostate underestimates the presence of cancer. Urology 50(4): 562-566, 1997. (Pubitemid 27433216)
12. Flanigan RC, Catalona WJ, Richie JP, Ahman FR, Hudson MA, Scardino PT, DeKernion JB, Ratliff TL, Kavoussi LR and Dalkin BL: Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer results of a multicenter clinical trial of 6,630 men. J Urol 152: 1506-1509, 1994. (Pubitemid 24326297)
13. Chon CH, Lai FC, McNeal JE and Presti JC Jr: Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J Urol 167(6): 2457-2460, 2002. (Pubitemid 34533145)
14. Patel AR, Jones JS, Rabets J, DeOreo G and Zippe CD: Parasagittal biopsies add minimal information in repeat saturation biopsy. Urology 63(1): 87-89, 2004. (Pubitemid 38147556)
15. Halpern EJ, Ramey JR, Strup SE, Frausher F, McCue P and Gomella LG: Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer 104(11): 2373-2383, 2005. (Pubitemid 41691558)
16. Frausher F, Klauser A, Vollger H, Halpern EJ, Pallwein L, Steiner H, Schuster A, Horninger W, Rogatsch H and Bartsch G: Comparison of contrast-enhanced color Doppler-targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol 167(4): 1648-1652, 2002. (Pubitemid 34240691)
17. Halpern EJ: Contrast-enhanced ultrasound imaging of prostate cancer. Rev Urol 8: S29-37, 2006.
18. Loch T: Computerized supported transrectal ultrasound (C-TRUS) in the diagnosis of prostate cancer. Urologe A 43(11): 1377-1384, 2004.
19. Rifkin MD and Choi H: Implications of small, peripheral hypoechoic lesions in endorectal US of the prostate. Radiology 166: 619-622, 1988. (Pubitemid 18058913)
20. Halpern EJ and Strup SE: Using gray-scale and color and power Doppler sonography to detect prostatic cancer. Am J Roentgenol 174: 623-627, 2000. (Pubitemid 30126236)
21. Pelzer A, Bektic J, Berger AP, Pallwein L, Halpern EJ, Horninger W, Bartsch G and Frausher F: Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 173: 1926-1929, 2005.
22. Taymoorian K, Thomas A, Slowinski T, Kniabanchian M, Stephan C, Lein M, Deger S, Lenk S, Loening SA and Fischer T: Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies. Anticancer Res 27(6C): 4315-4320, 2007.
23. Aigner F, Pallwein L, Mittenberg M, Pinggera GM, Mikuz G, Horninger W and Frausher F: Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate. BJU Int 103(4): 458-463, 2009.
24. Folkman J and Cotran R: Relation of vascular proliferation to tumour growth. Int Rev Exp Pathol 16: 207-248, 1976.
25. Kay PA, Robb RA and Bostwick DG: Prostate cancer microvessels: a novel method for three-dimensional reconstruction and analysis. Prostate 37: 270-277, 1998. (Pubitemid 28524660)
26. Halpern EJ, Rosenberg M and Gomella LG: Prostate cancer: contrast-enhanced us for detection. Radiology 219: 219-225, 2001.
27. Seitz M, Gratzke C, Schlenker B, Buchner A, Karl A, Roosen A, Singer BB, Bastian PJ, Ergün S, Stief CG, Reich O and Tilki D: Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrasht pulse sequence (CPS) technology for the identification of prostate cancer. Urol Oncol: Jun 11, 2009 (Epub ahead of print).
28. 111In-DTPA- labelled pegylated liposomes in a human tumour xenograft model. Br J Cancer 83: 684-688, 2000. (Pubitemid 30636313)
29. Mittenberg M, Pingera GM, Horninger W, Bartsch H, Schafer G, Brunner A, Halpern EJ, Gradl J, Pallwein L and Frauscher F: Comparision of contrast-enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. J Urol 178(2): 464-468, 2007. (Pubitemid 47030488)